27Dec
17Dec
Elizabeth Banks Puts Her Unique Stamp (and Face) on Archer Roose Wine
The deal that Elizabeth Banks has with Archer Roose, a premium canned wine brand, isn’t one of those superficial celebrity endorsements. As co-owner and chief creative officer, the Hollywood multi-hyphenate has embedded herself fully into the brand, both in real life and in a series of wacky ads over the past several years. By extension, and as a running gag, she’s also invaded the professional and personal life of its female founder Marian Leitner. For the latest campaign, Banks has...
14Dec
US winemakers revive sales with SMS marketing, sustainability and innovation
Bring the Wine to the People - As prices of bottles and tasting fees rise across wine country—but especially in premium regions like Napa Valley—winemakers are finding ways to offset declining sales and visits by bringing their wares to their most likely customers. There is nothing better than popping a cork to celebrate a major achievement or momentous occasion. But for younger drinkers who may only want one serving of alcohol, and are looking for something with a lighter carbon...
12Dec
Archer Roose Wines’ Rapid On-Premise Growth Continues, Inking National Distribution at Six New Restaurant and Hospitality Chains
Archer Roose, leading canned wine brand, is stacking up new wins in restaurant and hospitality properties around the country. Beginning now through January 2025, Archer Roose Wines will be placed across Levy Hospitality-served stadiums, arenas and venues, Atrium Hospitality-managed hotels, Vail Resort Group locations, STK Steakhouse and Kona Grill to-go menus, Old Chicago restaurants and Punch Bowl Social entertainment spaces. The new distribution deals come on the heels of recently-forged Archer Roose Wines placements at more than 150 Dave &...
12Dec
RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation
RevBio, Inc., announced that it has received FDA approval to expand its ongoing clinical trial to immediately fixate cranial flaps using TETRANITE®, the company’s bone adhesive biomaterial. The company also received reimbursement coverage from the Centers for Medicare and Medicaid (“CMS”) for the use of TETRANITE to replace metal plates and screws. Previously, RevBio received FDA approval to initiate a first-in-human clinical study for an initial five patients to restore cranial flaps following craniotomy procedures and to repair extradural use...
10Dec
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Corbus Pharmaceuticals Holdings, Inc., an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo. Read more >>
05Dec
Buffalo Next: CleanFiber secures $20M in federal funds to help expand nationally
With $20 million in grants secured from the U.S. Department of Energy, CleanFiber is opening new plants in Washington and Texas. These grants are part of more than $75 million in financing vehicles, grants, and tax credits the Buffalo-headquartered startup has secured in 2024. The company, which makes building insulation from recycled corrugated cardboard supporting energy efficiency, moved to Buffalo after winning $500,000 in the 43North business competition in 2016. The company was founded in Massachusetts in 2013 and was...
04Dec
Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment
Corbus Pharmaceuticals received a fast-track designation from the Food and Drug Administration for its treatment of relapsed or refractory metastatic cervical cancer. The Norwood, Mass., oncology company on Tuesday said the treatment, CRB-701, is being tested for safety and efficacy in a Phase 1 clinical trial in patients with advanced solid tumors known to be associated with high Nectin-4 expression. CRB-701 targets Nectin-4, which is a cell adhesion protein that is over-expressed in many types of human cancers. Corbus said...
03Dec
Wasabi Technologies Joins SINET Academic Information Network
Wasabi Technologies, the hot cloud storage company, today announced that it has joined SINET (Science Information NETwork), the academic information network provided by the National Institute of Informatics (NII), as a cloud storage service provider, enabling the availability of Wasabi hot cloud storage via SINET. Universities and research institutes using SINET can now use Wasabi hot cloud storage over SINET's high-speed and secure closed network. SINET is an information and telecommunications network built and operated by NII as an academic...
30Nov